Literature DB >> 14583885

Fatal hemophagocytic lymphohistiocytosis associated with Epstein-Barr virus infection in a patient with a novel mutation in the signaling lymphocytic activation molecule-associated protein.

Natasha B Halasa1, James A Whitlock, Thomas L McCurley, Jarrod A Smith, Quili Zhu, Hans Ochs, Terence S Dermody, James E Crowe.   

Abstract

Individuals with X-linked lymphoproliferative disease are susceptible to severe Epstein-Barr virus (EBV) infections that are often fatal. Mutations in signaling lymphocytic activation molecule-associated protein (SAP) are associated with this illness. We describe a patient with a novel serine-to-proline mutation at aa 57 in SAP and compare the location of the altered amino acid with all known missense mutations in the SAP-encoding SH2D1A gene, including those of 4 additional individuals whose cases have not been described elsewhere. The patient's genetic condition was discovered only after he exhibited an abnormal host response to primary EBV infection that resulted in hemophagocytic lymphohistiocytosis syndrome, which was complicated by marrow aplasia with terminal disseminated aspergillosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14583885     DOI: 10.1086/379126

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  5 in total

Review 1.  Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Los Angeles County.

Authors:  Theodoros Kelesidis; Romney Humphries; Dawn Terashita; Shahrooz Eshaghian; Mary C Territo; Jonathan Said; Michael Lewinski; Judith S Currier; David Pegues
Journal:  J Med Virol       Date:  2012-05       Impact factor: 2.327

2.  Characterization of a novel disease-causing mutation in exon 1 of SH2D1A gene through amplicon sequencing: a case report on HLH.

Authors:  Shiyuan Zhou; Hongyu Ma; Bo Gao; Guangming Fang; Yi Zeng; Qing Zhang; GaoFu Qi
Journal:  BMC Med Genet       Date:  2017-02-14       Impact factor: 2.103

3.  Ruxolitinib treatment permits lower cumulative glucocorticoid dosing in children with secondary hemophagocytic lymphohistiocytosis.

Authors:  Ying Chi; Rong Liu; Zhi-Xuan Zhou; Xiao-Dong Shi; Yu-Chuan Ding; Jian-Guo Li
Journal:  Pediatr Rheumatol Online J       Date:  2021-04-01       Impact factor: 3.054

Review 4.  Hemophagocytic lymphohistiocytosis: review of etiologies and management.

Authors:  Melissa R George
Journal:  J Blood Med       Date:  2014-06-12

5.  Hemophagocytic Lymphohistiocytosis in Intensive Care Unit: A 71-Case Strobe-Compliant Retrospective Study.

Authors:  Thomas Barba; Delphine Maucort-Boulch; Jean Iwaz; Julien Bohé; Jacques Ninet; Arnaud Hot; Jean-Christophe Lega; Claude Guérin; Laurent Argaud; Christiane Broussolle; Yvan Jamilloux; Jean-Christophe Richard; Pascal Sève
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.